Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03248635 · ClinicalTrials.gov registry record
Questionnaire Pre-Test Study
A clinical trial, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 30
- Enrollment target
NCT03248635: Completed study, sponsored by National Cancer Institute (NCI).
NCT03248635 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03248635 has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
Study Summary
Background: The Division of Cancer Epidemiology and Genetics does research into the causes of cancer and ways to prevent it. It uses data from questionnaires. Sometimes, pre-testing a questionnaire with a group of volunteers can help researchers find errors in it and learn ways to improve it. Objectives: To test a questionnaire for problems that might cause response errors and to develop ideas for improving it. To test how long it takes people to complete it. Eligibility: Adults ages 35-75. Volunteers both with and without a history of tobacco use and with or without a family history of cancer are needed. Design: Participants will be screened with a phone call. Participants will be told what background data to bring to the 1 study visit. An interviewer will give the participants the questionnaire. It will be done with pen and paper. It will take about 1 hour. There will be multiple-choice and open-ended questions. They will be about lifestyle, medical, and environmental factors. Some of the questions will be about possibly illegal or highly sensitive behaviors. Participants will note any questions that they find hard to answer for any reason. They will be asked to answer the best they can, but they can skip any question that they prefer not to answer. The personal data of participants will be deleted when the study is done. The interviewer will observe participants while they do the questionnaire. He or she will look for things like long pauses and confusion. Participants will discuss the exam with the interviewer after they finish. This will take about 1 hour.
Primary Outcome
Response errors and comments on interpretation of questions and response categories, and the duration needed to complete the questionnaire modules.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2018-05-25 |
| Est. Completion | 2020-04-02 |
What the finished NCT03248635 record still lists
NCT03248635 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT03248635 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03248635 about?
NCT03248635 is a clinical study titled "Questionnaire Pre-Test Study". Background: The Division of Cancer Epidemiology and Genetics does research into the causes of cancer and ways to prevent it. It uses data from questionnaires. Sometimes, pre-testing a questionnaire with a group of volunteers can help researchers find errors in it and learn ways to improve it. Obje...
What is the current status of trial NCT03248635?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2018-05-25. Estimated completion is 2020-04-02.
Who is sponsoring clinical trial NCT03248635?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI